. "1"^^ . "0"^^ . "Pain intensity was assessed using  visual analogue scale at  2 and 24 hours after the a knee arthroscopy in 225 patients. Polymorphisms CYP2D6*3,*4,*5,*6, and gene duplication, polymorphism C3435T, and G2677TA  in MDR1, polymorphism A118G in the OPRM1 and polymorphisms 10799GA and -25385CT in the PXR gene  were analyzed by PCR \u2013 RFLP. There were 156 patients elegible for"@en . "1"^^ . "2010-12-31+01:00"^^ . . . "2015-03-20+01:00"^^ . . . . . . . "Farmakogenetika analgetick\u00E9ho \u00FA\u010Dinku tramadolu p\u0159i l\u00E9\u010Db\u011B akutn\u00ED bolesti." . "2008-01-01+01:00"^^ . "Pharmacogenetics analgetic efficacy of tramadol in acute pain treatment."@en . " pharmacogenetics" . . . . " polymorphism" . "GP305/08/P069" . "2010-04-16+02:00"^^ . "Tramadol" . "Intezita bolesti byla hodnocena pomoc\u00ED visu\u00E1ln\u00ED analogov\u00E9 \u0161k\u00E1ly v \u010Dase 2 a 24 hodin po artroskopick\u00E9 operaci kolene v souboru 225 pacient\u016F. Polymorfizmy CYP2D6, MDR1, OPRM1 a PXR byly stanovov\u00E1ny metodou PCR-RFLP. Z celkov\u00E9ho soubory byla vyhodnocena data \u00FA\u010Dinnosti od 156 hodnotiteln\u00FDch pacient\u016F.  Pr\u016Fm\u011Brn\u00E9 hodnoty inici\u00E1ln\u00ED bolesti byla v hodnotiteln\u00E9m so"@cs . "Opioidn\u00ED analgezie po pod\u00E1n\u00ED tramadolu je p\u0159ev\u00E1\u017En\u011B zprost\u0159edkovan\u00E1 hlavn\u00EDm metabolitem O-demetyltramadolem (M1). Demetylace tramadolu na\u00A0 M1 je katalyzov\u00E1na jatern\u00EDm cytochromem P4502D6(CYP2D6), jeho\u017E aktivita je v\u00A0na\u0161\u00ED populaci polymorfn\u00ED. Nejni\u017E\u0161\u00ED koncentrace O-demetyltramadolu a nejvy\u0161\u0161\u00ED koncentrace mate\u0159sk\u00E9 l\u00E1tky jsou popisov\u00E1ny u pomal\u00FDch metaboliz\u00E1tor\u016F CYP2D6 ve srovn\u00E1n\u00ED s\u00A0rychl\u00FDmi metaboliz\u00E1tory. V\u00FDznam polymorfizmu CYP2D6 na analgetickou \u00FA\u010Dinnost a sn\u00E1\u0161enlivost l\u00E9\u010Diva nen\u00ED jasn\u00FD. N\u011Bkter\u00E9 popisuj\u00ED podstatn\u00FD rozd\u00EDl v\u00A0analgetick\u00E9 \u00FA\u010Dinnosti nebo sn\u00E1\u0161enlivosti\u00A0 tramadolu v\u00A0z\u00E1vislosti na aktivit\u011B CYP2D6, zat\u00EDmco jin\u00ED auto\u0159i tak\u00E9v\u00E9to rozd\u00EDly nepozorovali.\u00A0\u00A0V\u00FDsledky na\u0161\u00ED pilotn\u00ED studie nav\u00EDc ukazuj\u00ED, \u017Ee absorpce tramadolu je z\u00E1visl\u00E1 na p\u0159\u00EDtomnosti polymorfizmu C3435T v\u00A0genu MDR1. V\u00FDznam polymorfizm\u016F MDR1, PXR nebo u-opioidn\u00EDch receptor\u016F na \u00FA\u010Dinnost l\u00E9\u010Diva nen\u00ED zn\u00E1m. Pracovn\u00ED hypot\u00E9za je, \u017Ee polymorfizmy v\u00A0uveden\u00FDch genech jsou v\u00FDznamn\u00FDmi faktory ovliv\u0148uj\u00EDc\u00EDmi farmakokinetiku l\u00E9\u010Diva" . . . . . . "0"^^ . "Opioid analgesia after tramadol administration is mainly mediated by the main active metabolite O-demethyltramadol (M1). Demethylation of the parent compound forming M1\u00A0 is catalyzed by liver cytochrome P4502D6 (CYP2D6), which is a highly polymorphic enzyme in our population. Lower plasma concentrations\u00A0corresponding to higher plasma levels of parent compoud were observed in poor metabolizers of CYP2D6 compared to extensive metabolizers. Results of our pilot study show that the absorption of tramadolafter peroral administration is dependent on C3435T polymorphism in MDR1 gene. However, clinical importance of CYP2D6 polymorphism is not clear and the influence of known functional polymorphisms in MDR1, PXR or u-opioid receptor genes have not been studied, yet. Our hypothesis is that polymorphisms in these genes are major factor affecting the pharmacokinetics of the drug and its opioid efficacy. These sources of interindividual variability represent an important and unrecognized factor, which is"@en . . . "http://www.isvav.cz/projectDetail.do?rowId=GP305/08/P069"^^ . "1"^^ . "Tramadol; pharmacogenetics; polymorphism; metabolism."@en .